Results 21 to 30 of about 14,081 (169)

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT-OES-1 Trial. [PDF]

Int J Cancer
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
van der Zijden CJ, Huizer TJ, Eyck BM, van der Gaast A, van Doorn L, Homs MYV, van Lanschot JJB, Nuyttens JJME, Oudijk L, Spaander MCW, Wijnhoven BPL, Mostert B, Lagarde SM.   +12 more
europepmc   +2 more sources

oligometastatic review

, 2021
Meta-analysis of prognosis of oligometastatic ...
petrelli, F (via Mendeley Data)
core   +1 more source

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer

Frontiers in Oncology, 2021
BackgroundTo assess the distribution characteristics and the prognostic value of immune infiltration in female oligometastatic breast cancer patients.MethodsWe retrospectively analyzed the clinicopathological data of oligometastatic breast cancer (OMBC ...
Danyang Zhou, Kuikui Jiang, Ruoxi Hong, Qianyi Lu, Wen Xia, Mei Li, Chengyou Zheng, Qiufan Zheng, Fei Xu, Shusen Wang   +9 more
doaj   +1 more source

oligometastatic F1000

, 2021
metaanalysis of oligometastatic ...
petrelli, fausto
core   +1 more source

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

Frontiers in Oncology, 2020
BackgroundLocal ablative treatments improve survival in patients with oligometastatic disease in addition to chemotherapy. The application of immune checkpoint inhibitors prolonged patients’ survival in different tumor entities.
Philipp Schubert, Philipp Schubert, Sandra Rutzner, Sandra Rutzner, Markus Eckstein, Markus Eckstein, Benjamin Frey, Benjamin Frey, Claudia Schweizer, Claudia Schweizer, Marlen Haderlein, Marlen Haderlein, Sebastian Lettmaier, Sebastian Lettmaier, Sabine Semrau, Sabine Semrau, Antoniu-Oreste Gostian, Antoniu-Oreste Gostian, Jian-Guo Zhou, Jian-Guo Zhou, Jian-Guo Zhou, Udo S. Gaipl, Udo S. Gaipl, Rainer Fietkau, Rainer Fietkau, Markus Hecht, Markus Hecht   +26 more
doaj   +1 more source

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac [PDF]

, 2022
The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients ...
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium
core  

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Frontiers in Oncology, 2022
The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 ...
Andrea Botticelli, Andrea Botticelli, Agnese Fabbri, Michela Roberto, Michela Roberto, Daniele Alesini, Alessio Cirillo, Alessio Cirillo, Giuliana D’Auria, Eriseld Krasniqi, Eleonora Marrucci, Margherita Muratore, Francesco Pantano, Laura Pizzuti, Ilaria Portarena, Rosalina Rossi, Simone Scagnoli, Simone Scagnoli, Paolo Marchetti, Paolo Marchetti   +19 more
doaj   +1 more source

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

, 2022
Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct entity that is different from localized and disseminated diseases. The definition of oligometastatic NSCLC varies across studies in past decades owing to the use of different imaging ...
Ue-Cheung Ho, Yi-Hsing Chen, Lu-Ting Kuo
core   +1 more source

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

Frontiers in Oncology, 2023
Oligometastatic progression represents a unique manifestation of tumor immune-escape that can lead to disease progression during treatment with immune checkpoint inhibitor (ICI). The diagnosis and further optimal management of oligometastatic progression
Karam Khaddour, Alice Zhou, Omar Butt, Jiayi Huang, George Ansstas   +4 more
doaj   +1 more source

Defining oligometastatic non-small cell lung cancer

, 2021
Objective: In this review, the concept of (synchronous) oligometastatic disease in patients with non-oncogene-driven non-small cell lung cancer (NSCLC) will be placed in the context of tumor biology and metastatic growth patterns.
A.C. (Anne-Marie) Dingemans, R. (Robin) Cornelissen, D.W. (Daphne) Dumoulin, J.B.W. (Jos) Elbers, A.P.W.M. Maat, J.H. (Jan) von der Thüsen, J.F. (Jill) Mentink, M.S. (Marthe) Paats   +7 more
core   +1 more source